vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v16i1.1691vsp-1727Research ArticleОБЗОР ЛИТЕРАТУРЫREVIEWВакцинация пациентов с ювенильным идиопатическим артритом против пневмококка: обзор международного опытаPneumococcal Vaccination of Patients with Juvenile Idiopathic Arthritis: Review of International ExperienceСолошенкоМ. А.SoloshenkoMargarita A.https://orcid.org/0000-0002-3874-4721АлексееваЕ. И.AlekseevaEkaterina I.

чл.-корр. РАН, профессор, заведующая ревматологическим отделением ННПЦЗД, декан педиатрического факультета Первого МГМУ им. И.М. Сеченова

alekatya@yandex.ruБзароваТ. М.BzarovaTatiana M.ИсаеваК. Б.IsaevaKseniya B.ДенисоваР. В.DenisovaRina V.ЛомакинаО. Л.LomakinaOlga L.КащенкоЕ. М.KaschenkoElena M.КарасёваА. В.KarasevaAnna V.Национальный научно-практический центр здоровья детей Минздрава РоссииРоссияNational Scientific and Practical Center of Children’s Health, Ministry of Health of the Russian FederationRussian FederationНациональный научно-практический центр здоровья детей Минздрава России, Первый Московский государственный медицинский университет им. И.М. СеченоваРоссияNational Scientific and Practical Center of Children’s Health, Ministry of Health of the Russian Federation, Sechenov First Moscow State Medical UniversityRussian Federation2017060420171612428Copyright © Солошенко М.А., Алексеева Е.И., Бзарова Т.М., Исаева К.Б., Денисова Р.В., Ломакина О.Л., Кащенко Е.М., Карасёва А.В., 20172017Солошенко М.А., Алексеева Е.И., Бзарова Т.М., Исаева К.Б., Денисова Р.В., Ломакина О.Л., Кащенко Е.М., Карасёва А.В.Soloshenko M.A., Alekseeva E.I., Bzarova T.M., Isaeva K.B., Denisova R.V., Lomakina O.L., Kaschenko E.M., Karaseva A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/1727

В обзоре обобщен международный опыт иммунизации пациентов с ювенильным идиопатическим артритом (ЮИА) против пневмококка. Показана высокая  эффективность и безопасность пневмококковых вакцин у детей с ЮИА. Многочисленные исследования демонстрируют адекватный иммунный ответ после вакцинации даже на фоне терапии иммуносупрессивными и генно-инженерными биологическими препаратами. Профилактика пневмококковой инфекции позволяет предотвратить развитие пневмоний у больных ЮИА.

This review summarizes the international experience of pneumococcal immunization of patients with juvenile idiopathic arthritis (JIA). The high efficiency and safety of pneumococcal vaccines in children with JIA is shown. Numerous studies have demonstrated an adequate immune response after vaccination even during therapy with immunosuppressive and genetically engineered biological agents drugs. Prevention of the pneumococcal infection helps avoid the development of pneumonia in patients with JIA.

детиювенильный идиопатический артритвакцинацияпневмококковая инфекцияпрофилактикабезопасностьchildrenjuvenile idiopathic arthritisvaccinationpneumococcal infectionpreventionsafetyReferencesАлексеева Е.И., Литвицкий П.Ф. Ювенильный ревматоидный артрит: этиология, патогенез, клиника, алгоритмы диагностики и лечения. Руководство для врачей, преподавателей, научных сотрудников / Под общей ред. А.А. Баранова. — М.: ВЕДИ; 2007. — 368 с. [Alexeeva EI, Litvitskii PF. Yuvenil’nyi revmatoidnyi artrit: etiologiya, patogenez, klinika, algoritmy diagnostiki i lecheniya. Rukovodstvo dlya vrachei, prepodavatelei, nauchnykh sotrudnikov. Ed by Baranov A.A. Moscow: VEDI; 2007. 368 p. (In Russ).]Алексеева Е.И., Литвицкий П.Ф. Ювенильный ревматоидный артрит: этиология, патогенез, клиника, алгоритмы диагностики и лечения. Руководство для врачей, преподавателей, научных сотрудников / Под общей ред. А.А. Баранова. — М.: ВЕДИ; 2007. — 368 с. [Alexeeva EI, Litvitskii PF. Yuvenil’nyi revmatoidnyi artrit: etiologiya, patogenez, klinika, algoritmy diagnostiki i lecheniya. Rukovodstvo dlya vrachei, prepodavatelei, nauchnykh sotrudnikov. Ed by Baranov A.A. Moscow: VEDI; 2007. 368 p. (In Russ).]Гольдштейн А.В. Вакцинопрофилактика пневмококковой инфекции // Вакцинация. — 2004. — № 2 — С. 10–11. [Gol’dshtein AV. Vaktsinoprofilaktika pnevmokokkovoi infektsii. Vaktsinatsiya. 2004;(2):10–11. (In Russ).]Гольдштейн А.В. Вакцинопрофилактика пневмококковой инфекции // Вакцинация. — 2004. — № 2 — С. 10–11. [Gol’dshtein AV. Vaktsinoprofilaktika pnevmokokkovoi infektsii. Vaktsinatsiya. 2004;(2):10–11. (In Russ).]Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46(9):2287–2293. doi: 10.1002/art.10524.Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46(9):2287–2293. doi: 10.1002/art.10524.Лыскина Г.А. Вторичная инфекция и возможности ее лечения и профилактики при системных заболеваниях соединительной ткани у детей / Сб. тезисов IX Российского Национального конгресса «Человек и лекарство». — М.; 2002. [Lyskina GA. Vtorichnaya infektsiya i vozmozhnosti ee lecheniya i profilaktiki pri sistemnykh zabolevaniyakh soedinitel’noi tkani u detei. In: (Conference proceedings) Sb. tezisov IX Rossiiskogo Natsional’nogo kongressa «Chelovek i lekarstvo». Moscow; 2002. (In Russ).]Лыскина Г.А. Вторичная инфекция и возможности ее лечения и профилактики при системных заболеваниях соединительной ткани у детей / Сб. тезисов IX Российского Национального конгресса «Человек и лекарство». — М.; 2002. [Lyskina GA. Vtorichnaya infektsiya i vozmozhnosti ee lecheniya i profilaktiki pri sistemnykh zabolevaniyakh soedinitel’noi tkani u detei. In: (Conference proceedings) Sb. tezisov IX Rossiiskogo Natsional’nogo kongressa «Chelovek i lekarstvo». Moscow; 2002. (In Russ).]Бзарова Т.М., Алексеева Е.И., Валиева С.И., и др. Безопасность применения ингибиторов фактора некроза опухоли во взрослой и детской ревматологической практике // Вопросы современной педиатрии. — 2010. — Т. 9. — № 1 — С. 82–94. [Bzarova TM, Alexeeva EI, Valieva SI, et al. Safety of tumor necrosis factor blockers in adult’s and children’s rheumatologic practice. Current pediatrics. 2010;9(1):82–94. (In Russ).]Бзарова Т.М., Алексеева Е.И., Валиева С.И., и др. Безопасность применения ингибиторов фактора некроза опухоли во взрослой и детской ревматологической практике // Вопросы современной педиатрии. — 2010. — Т. 9. — № 1 — С. 82–94. [Bzarova TM, Alexeeva EI, Valieva SI, et al. Safety of tumor necrosis factor blockers in adult’s and children’s rheumatologic practice. Current pediatrics. 2010;9(1):82–94. (In Russ).]Alexeeva EI, Valieva SI, Bzarova TM, et al. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin Rheumatol. 2011;30(9): 1163–1172. doi: 10.1007/s10067-011-1720-7.Alexeeva EI, Valieva SI, Bzarova TM, et al. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin Rheumatol. 2011;30(9): 1163–1172. doi: 10.1007/s10067-011-1720-7.Thakur A, Pedersen LE, Jungersen G. Immune markers and correlates of protection for vaccine induced immune responses. Vaccine. 2012;30(33):4907–4920. doi: 10.1016/j.vaccine.2012.05.049.Thakur A, Pedersen LE, Jungersen G. Immune markers and correlates of protection for vaccine induced immune responses. Vaccine. 2012;30(33):4907–4920. doi: 10.1016/j.vaccine.2012.05.049.Репина И.Б., Галкина Л.А. Вакцинация детей с осложненным преморбидным фоном. Учебное пособие. — М.: ГБУЗ МО МОНИКИ; 2015. — 32 с. [Repina IB, Galkina LA. Vaktsinatsiya detei s oslozhnennym premorbidnym fonom. Uchebnoe posobie. Moscow: GBUZ MO MONIKI; 2015. 32 p. (In Russ).]Репина И.Б., Галкина Л.А. Вакцинация детей с осложненным преморбидным фоном. Учебное пособие. — М.: ГБУЗ МО МОНИКИ; 2015. — 32 с. [Repina IB, Galkina LA. Vaktsinatsiya detei s oslozhnennym premorbidnym fonom. Uchebnoe posobie. Moscow: GBUZ MO MONIKI; 2015. 32 p. (In Russ).]Шамшева О.В., Скачкова Л.О., Поляков В.Г., Михайлова С.Н. Вакцинация детей с хронической патологией // Педиатрия. Журнал им. Г.Н. Сперанского. Спецвыпуск «Инфекционные болезни у детей». — 2001. — С. 67–72. [Shamsheva OV, Skachkova LO, Polyakov VG, Mikhailova SN. Vaktsinatsiya detei s khronicheskoi patologiei. Pediatriia. Spetsvypusk «Infektsionnye bolezni u detei». 2001;67–72. (In Russ).]Шамшева О.В., Скачкова Л.О., Поляков В.Г., Михайлова С.Н. Вакцинация детей с хронической патологией // Педиатрия. Журнал им. Г.Н. Сперанского. Спецвыпуск «Инфекционные болезни у детей». — 2001. — С. 67–72. [Shamsheva OV, Skachkova LO, Polyakov VG, Mikhailova SN. Vaktsinatsiya detei s khronicheskoi patologiei. Pediatriia. Spetsvypusk «Infektsionnye bolezni u detei». 2001;67–72. (In Russ).]Костинов М.П., Тарасова А.А. Вакцинопрофилактика пневмококковой инфекции и гриппа при аутоиммунных заболеваниях. Руководство для врачей. — М.: МДВ; 2009. — 252 с. / Kostinov M.P., Tarasova A.A. [Kostinov MP, Tarasova AA. Vaktsinoprofilaktika pnevmokokkovoi infektsii i grippa pri autoimmunnykh zabolevaniyakh. Rukovodstvo dlya vrachei. Moscow: MDV; 2009: 252 p. (In Russ).]Костинов М.П., Тарасова А.А. Вакцинопрофилактика пневмококковой инфекции и гриппа при аутоиммунных заболеваниях. Руководство для врачей. — М.: МДВ; 2009. — 252 с. / Kostinov M.P., Tarasova A.A. [Kostinov MP, Tarasova AA. Vaktsinoprofilaktika pnevmokokkovoi infektsii i grippa pri autoimmunnykh zabolevaniyakh. Rukovodstvo dlya vrachei. Moscow: MDV; 2009: 252 p. (In Russ).]Pneumococcal vaccines WHO position paper 2012. Wkly Epidemiol Rec. 2012;87(14):129–144.Pneumococcal vaccines WHO position paper 2012. Wkly Epidemiol Rec. 2012;87(14):129–144.Hmamouchi I, Winthrop K, Launay O, Dougados M. Low rate of influenza and pneumococcal vaccine coverage in rheumatoid arthritis: data from the international COMORA cohort. Vaccine. 2015;33(12):1446–1452. doi: 10.1016/j.vaccine.2015.01.065.Hmamouchi I, Winthrop K, Launay O, Dougados M. Low rate of influenza and pneumococcal vaccine coverage in rheumatoid arthritis: data from the international COMORA cohort. Vaccine. 2015;33(12):1446–1452. doi: 10.1016/j.vaccine.2015.01.065.Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep. 2010 Sep 3; 59(34):1102-6.Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep. 2010 Sep 3; 59(34):1102-6.Федеральные клинические рекомендации по вакцинопрофилактике пневмококковой инфекции у детей. — М.; 2015. [Federal’nye klinicheskie rekomendatsii po vaktsinoprofilaktike pnevmokokkovoi infektsii u detei. Moscow; 2015. (In Russ).] Доступно по: http://www.pediatr-russia.ru/sites/default/files/file/kr_pnev.pdf. Ссылка активна на 21.02.2017.Федеральные клинические рекомендации по вакцинопрофилактике пневмококковой инфекции у детей. — М.; 2015. [Federal’nye klinicheskie rekomendatsii po vaktsinoprofilaktike pnevmokokkovoi infektsii u detei. Moscow; 2015. (In Russ).] Доступно по: http://www.pediatr-russia.ru/sites/default/files/file/kr_pnev.pdf. Ссылка активна на 21.02.2017.Pneumococcal conjugate vaccine for childhood immunization — WHO position paper. Weekly Epid. Rec. 2007; 82 (12): 93–104.Pneumococcal conjugate vaccine for childhood immunization — WHO position paper. Weekly Epid. Rec. 2007; 82 (12): 93–104.Muller-Ladner C, Muller-Ladner U; European League Against Rheumatism. [Vaccinations in patients with autoimmune inflammatory rheumatic diseases--EULAR recommendations for pediatric and adult patients. (In German).] Med Monatsschr Pharm. 2012;35(10):353–366.Muller-Ladner C, Muller-Ladner U; European League Against Rheumatism. [Vaccinations in patients with autoimmune inflammatory rheumatic diseases--EULAR recommendations for pediatric and adult patients. (In German).] Med Monatsschr Pharm. 2012;35(10):353–366.Nagel J, Geborek P, Saxne T, et al. The risk of pneumococcal infections after immunization with pneumococcal conjugate vaccine compared to non-vaccinated inflammatory arthritis patients. Scand J Rheumatol. 2015;44(4):271–279. doi: 10.3109/03009742.2014.984754.Nagel J, Geborek P, Saxne T, et al. The risk of pneumococcal infections after immunization with pneumococcal conjugate vaccine compared to non-vaccinated inflammatory arthritis patients. Scand J Rheumatol. 2015;44(4):271–279. doi: 10.3109/03009742.2014.984754.Nagel J, Geborek P, Saxne T, et al. The association between antibody levels before and after 7-valent pneumococcal conjugate vaccine immunization and subsequent pneumococcal infection in chronic arthritis patients. Arthritis Res Ther. 2015;17:124. doi: 10.1186/s13075-015-0636-z.Nagel J, Geborek P, Saxne T, et al. The association between antibody levels before and after 7-valent pneumococcal conjugate vaccine immunization and subsequent pneumococcal infection in chronic arthritis patients. Arthritis Res Ther. 2015;17:124. doi: 10.1186/s13075-015-0636-z.Kapetanovic MC, Saxne T, Jonsson G, et al. Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis. Arthritis Res Ther. 2013;15(5):R171. doi: 10.1186/ar4358.Kapetanovic MC, Saxne T, Jonsson G, et al. Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis. Arthritis Res Ther. 2013;15(5):R171. doi: 10.1186/ar4358.Kapetanovic MC, Roseman C, Jonsson G, et al. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors. Arthritis Rheum. 2011;63(12):3723-3732. doi: 10.1002/art.30580.Kapetanovic MC, Roseman C, Jonsson G, et al. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors. Arthritis Rheum. 2011;63(12):3723-3732. doi: 10.1002/art.30580.Kapetanovic MC, Saxne T, Sjoholm A, et al. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford). 2006;45(1):106–111. doi:10.1093/rheumatology/kei193.Kapetanovic MC, Saxne T, Sjoholm A, et al. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford). 2006;45(1):106–111. doi:10.1093/rheumatology/kei193.Winthrop KL, Silverfield J, Racewicz A, et al. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Ann Rheum Dis. 2016;75(4):687–695. doi: 10.1136/annrheumdis-2014-207191.Winthrop KL, Silverfield J, Racewicz A, et al. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Ann Rheum Dis. 2016;75(4):687–695. doi: 10.1136/annrheumdis-2014-207191.Migita K, Akeda Y, Akazawa M, et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus. Arthritis Res Ther. 2015;17:149. doi: 10.1186/s13075-015-0662-x x.Migita K, Akeda Y, Akazawa M, et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus. Arthritis Res Ther. 2015;17:149. doi: 10.1186/s13075-015-0662-x x.Coulson E, Saravanan V, Hamilton J, et al. Pneumococcal antibody levels after pneumovax in patients with rheumatoid arthritis on methotrexate. Ann Rheum Dis. 2011;70(7):1289–1291. doi: 10.1136/ard.2010.144451. (Erratum in Ann Rheum Dis. 2012;71(1):158. Long, Kin So [corrected to So, Kin Long]. http://ard.bmj.com/content/70/7/1289.long)Coulson E, Saravanan V, Hamilton J, et al. Pneumococcal antibody levels after pneumovax in patients with rheumatoid arthritis on methotrexate. Ann Rheum Dis. 2011;70(7):1289–1291. doi: 10.1136/ard.2010.144451. (Erratum in Ann Rheum Dis. 2012;71(1):158. Long, Kin So [corrected to So, Kin Long]. http://ard.bmj.com/content/70/7/1289.long)Bingham CO 3rd, Looney RJ, Deodhar A, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthr Rheum. 2010;62(1): 64–74. doi: 10.1002/art.25034.Bingham CO 3rd, Looney RJ, Deodhar A, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthr Rheum. 2010;62(1): 64–74. doi: 10.1002/art.25034.Schiff M, Kaell A, Tay L, et al. Response to pneumococcal vaccine in rheumatoid arthritis patients with an inadequate response to anti-TNF therapy treated with abatacept in the ARRIVE trial. Ann Rheum Dis. 2007;66(Suppl II):437.Schiff M, Kaell A, Tay L, et al. Response to pneumococcal vaccine in rheumatoid arthritis patients with an inadequate response to anti-TNF therapy treated with abatacept in the ARRIVE trial. Ann Rheum Dis. 2007;66(Suppl II):437.Aikawa NE, Franca IL, Ribeiro AC, et al. Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy. Vaccine. 2015;33(5):604–609. doi: 10.1016/j.vaccine.2014.12.030.Aikawa NE, Franca IL, Ribeiro AC, et al. Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy. Vaccine. 2015;33(5):604–609. doi: 10.1016/j.vaccine.2014.12.030.Farmaki E, Kanakoudi-Tsakalidou F, Spoulou V, et al. The effect of anti-TNF treatment on the immunogenicity and safety of the 7-valent conjugate pneumococcal vaccine in children with juvenile idiopathic arthritis. Vaccine. 2010;28(31):5109–5113. doi: 10.1016/j.vaccine.2010.03.080.Farmaki E, Kanakoudi-Tsakalidou F, Spoulou V, et al. The effect of anti-TNF treatment on the immunogenicity and safety of the 7-valent conjugate pneumococcal vaccine in children with juvenile idiopathic arthritis. Vaccine. 2010;28(31):5109–5113. doi: 10.1016/j.vaccine.2010.03.080.Maglione MA, Das L, Raaen L, et al. Safety of vaccines used for routine immunization of U.S. children: a systematic review. Pediatrics. 2014;134(2):325–337. doi: 10.1542/peds.2014-1079.Maglione MA, Das L, Raaen L, et al. Safety of vaccines used for routine immunization of U.S. children: a systematic review. Pediatrics. 2014;134(2):325–337. doi: 10.1542/peds.2014-1079.Heijstek MW, Ott de Bruin LM, Bijl M, et al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis. 2011;70(10):1704–1712. doi: 10.1136/ard.2011.150193.Heijstek MW, Ott de Bruin LM, Bijl M, et al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis. 2011;70(10):1704–1712. doi: 10.1136/ard.2011.150193.Brenol CV, da Mota LM, Cruz BA, et al. [2012 Brazilian Society of Rheumatology Consensus on vaccination of patients with rheumatoid arthritis. (In English, Portuguese).] Rev Bras Reumatol. 2013;53(1):4–23. doi: 10.1590/S0482-50042013000100002.Brenol CV, da Mota LM, Cruz BA, et al. [2012 Brazilian Society of Rheumatology Consensus on vaccination of patients with rheumatoid arthritis. (In English, Portuguese).] Rev Bras Reumatol. 2013;53(1):4–23. doi: 10.1590/S0482-50042013000100002.Prelog M. Vaccination in patients with rheumatoid arthritis receiving immunotherapies. J Clin Cell Immunol. 2013;S6:007. doi: 10.4172/2155-9899.S6-007.Prelog M. Vaccination in patients with rheumatoid arthritis receiving immunotherapies. J Clin Cell Immunol. 2013;S6:007. doi: 10.4172/2155-9899.S6-007.Wiedermann U, Sitte HH, Burgmann H, et al. [Guidelines for vaccination of immunocompromised individuals. (In German).] Wien Klin Wochenschr. 2016;128 Suppl 4:337–376. doi: 10.1007/s00508-016-1033-6.Wiedermann U, Sitte HH, Burgmann H, et al. [Guidelines for vaccination of immunocompromised individuals. (In German).] Wien Klin Wochenschr. 2016;128 Suppl 4:337–376. doi: 10.1007/s00508-016-1033-6.

The authors declare that there are no conflicts of interest present.